Terms: = Prostate cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Diagnosis
83 results:
1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
2. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
3. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
4. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
5. New Molecular Markers for prostate cancer diagnosis.
Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
[TBL] [Abstract] [Full Text] [Related]
6. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant prostate cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract] [Full Text] [Related]
7. Genetic mutations in smoking-associated prostate cancer.
Elshafei A; Al-Toubat M; Feibus AH; Koul K; Jazayeri SB; Lelani N; Henry V; Balaji KC
Prostate; 2023 Sep; 83(13):1229-1237. PubMed ID: 37455402
[TBL] [Abstract] [Full Text] [Related]
8.
Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
[TBL] [Abstract] [Full Text] [Related]
9. Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with prostate cancer.
Iyer HS; Kensler KH; Vaselkiv JB; Stopsack KH; Roscoe C; Bandera EV; Qin B; Jang TL; Lotan TL; James P; Hart JE; Mucci LA; Laden F; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1120-1123. PubMed ID: 37249585
[TBL] [Abstract] [Full Text] [Related]
10. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract] [Full Text] [Related]
11. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
[TBL] [Abstract] [Full Text] [Related]
12. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents.
Hashemi M; Mirdamadi MSA; Talebi Y; Khaniabad N; Banaei G; Daneii P; Gholami S; Ghorbani A; Tavakolpournegari A; Farsani ZM; Zarrabi A; Nabavi N; Zandieh MA; Rashidi M; Taheriazam A; Entezari M; Khan H
Pharmacol Res; 2023 Jan; 187():106568. PubMed ID: 36423787
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention.
Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
[TBL] [Abstract] [Full Text] [Related]
14. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
15. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
16. DNA-gold nanoprobe-based integrated biosensing technology for non-invasive liquid biopsy of serum miRNA: A new frontier in prostate cancer diagnosis.
Kshirsagar P; Seshacharyulu P; Muniyan S; Rachagani S; Smith LM; Thompson C; Shah A; Mallya K; Kumar S; Jain M; Batra SK
Nanomedicine; 2022 Jul; 43():102566. PubMed ID: 35569810
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Features of Lung-Recurrent Hormone-Sensitive prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
18. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling.
Entezari M; Ghanbarirad M; Taheriazam A; Sadrkhanloo M; Zabolian A; Goharrizi MASB; Hushmandi K; Aref AR; Ashrafizadeh M; Zarrabi A; Nabavi N; Rabiee N; Hashemi M; Samarghandian S
Biomed Pharmacother; 2022 Jun; 150():112963. PubMed ID: 35468579
[TBL] [Abstract] [Full Text] [Related]
19. Identification of Potential Key Genes in prostate cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.
Khan MM; Mohsen MT; Malik MZ; Bagabir SA; Alkhanani MF; Haque S; Serajuddin M; Bharadwaj M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456461
[TBL] [Abstract] [Full Text] [Related]
20. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal prostate cancer.
Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
[TBL] [Abstract] [Full Text] [Related]
[Next]
